Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Recipients

Scholarships Awarded to Nine Students Affected by Dermatologic Conditions

Bausch Health Companies Inc. (NYSETSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the recipients of their 2021 Aspire Higher scholarship program. The program, which began in 2012, will award nine students who have been treated for a dermatologic condition with a scholarship of up to $10,000 to pursue their undergraduate or graduate degrees.

"For nine years, Ortho Dermatologics has supported students in achieving their higher education goals through our Aspire Higher scholarship program. Beyond the demands of their schooling and extracurricular activities, these students have also had to manage the burden of living with a skin condition," said Scott Hirsch , senior vice president and chief strategy officer, Bausch Health, and president, Ortho Dermatologics. "The stories our 2021 scholarship recipients shared with us are inspiring, and we are honored to provide them with this award to recognize their achievements and help them pursue their academic aspirations."

The 2021 honorees were chosen from nearly 150 applications and were selected in part due to their essays overviewing their educational journeys while living with dermatologic conditions and the role a health care professional played in treating the condition. The applications were judged by an independent panel of dermatologists from across the country.

The Aspire Higher scholarship program recognizes students across a wide range of educational pursuits, with scholarships in three categories, including the Undergraduate Scholar Awards, the Graduate Scholar Awards, and the Today's Woman Scholar Awards for mothers pursuing undergraduate or graduate degrees.

The 2021 Aspire Higher scholarship program recipients are:

  • Undergraduate Scholar Awards
    • Sonia Goyal , Clarksville, Md. – The George Washington University
    • Anhthy Nguyen , Hayward, Calif. University of California, Los Angeles
    • Olivia Kenyon , West Chester, Pa. University of Florida
  • Graduate Scholar Awards
    • McKenzie White , Bakersfield, Calif. – Rocky Vista University College of Osteopathic Medicine
    • Maria Rose Belding , Washington, D.C. Georgetown University School of Medicine
    • Brooke Abzug , Delray Beach, Fla. University of Florida : Department of Occupational Therapy
  • Today's Woman Scholar Awards
    • Megan Gambino , Doylestown, Pa. – Delaware Valley University
    • Hillary Hardin , North Bergen , N.J. – Felician University
    • Sarah Ramirez , Humble, Texas Lake Erie College of Osteopathic Medicine (LECOM), Bradenton Campus

"Living with a skin condition can often be very difficult, especially when managing school – much of which was particularly challenging this year due to remote learning – and other activities. Thanks to the generosity of Ortho Dermatologics, I will be one step further toward achieving my goal of receiving a degree in Physical Therapy and Exercise Science," said Hillary Hardin , Felician University, North Bergen, N.J.

To learn more about the Aspire Higher scholarship program and to see stories from previous scholarship recipients, please visit www.AspireHigherScholarships.com . The 2022 Aspire Higher scholarship program will be accepting applications in early 2022.

About the Aspire Higher Scholarship Program
Since 2013, the Aspire Higher scholarship program has awarded 60 scholarships, providing students a total of $648,000 toward their higher education on campuses nationwide. The Aspire Higher scholarship program is now funded through the Bausch Foundation.

About the Bausch Foundation
In 2017, the Bausch Foundation was established to improve the lives of patients globally by providing access to safe, effective medicines and by financially supporting health care education and causes. Since its inception, the Bausch Foundation has contributed millions of dollars worth of financial and product donations to global charitable health organizations.

About Ortho Dermatologics
Ortho Dermatologics is one of the largest dermatology businesses dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. In addition, the Ortho Dermatologics portfolio also includes several leading medical device systems for aesthetic applications, such as skin tightening and resurfacing, laser hair removal and other preventative therapeutic skin care treatments. More information can be found at www.ortho-dermatologics.com .

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn .

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Ortho Dermatologics is a trademark of Ortho Dermatologics' affiliated entities.
  © 2021 Ortho Dermatologics' affiliated entities.
ORD.0126.USA.21

Bausch Health Investor Contact:
Arthur Shannon
arthur.shannon@bauschhealth.com
(514) 865-3855
(877) 281-6642 (toll free)

Bausch Health Media Contact:
Lainie Keller
lainie.keller@bauschhealth.com
(908) 927-1198

Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

(PRNewsfoto/Valeant Pharmaceuticals Interna)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/ortho-dermatologics-announces-2021-aspire-higher-scholarship-recipients-301343645.html

SOURCE Bausch Health Companies Inc.

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO

"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is one of several options being considered to complete the separation. That process is ongoing. No decision has been reached to proceed with any particular transaction, and there can be no assurance that it will result in a transaction.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Medtronic announces cash dividend for third quarter of fiscal year 2025

The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0 .70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on January 10, 2025 to shareholders of record at the close of business on December 27, 2024 .

About Medtronic
Bold thinking. Bolder actions. We are Medtronic . Medtronic plc , headquartered in Galway , Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic , visit www.Medtronic.com and follow Medtronic on LinkedIn .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cardiex Limited (ASX:CDX)

Cardiex Limited


Keep reading...Show less

Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation Awareness Day

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support to the many patients impacted by OIC

"As an organization dedicated to supporting individuals living with pain conditions, we're proud to participate in this year's OIC Awareness Day," said Kathy Sapp, CEO of ACPA. "By increasing awareness and improving communication between healthcare providers, patients, and caregivers, we can make a meaningful difference for those affected by this commonly occurring condition."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Global Medical Service Robotics Market Project to Exceed $20 Billion in 2024 with Additional Growth Expected

FN Media Group News Commentary - Innovations in robotics technology, including artificial intelligence machine learning, and sensor technology, are enhancing the capabilities of medical robots. These advancements enable more precise surgical procedures, improved rehabilitation processes, and efficient hospital logistics, thus attracting more healthcare facilities to adopt robotic solutions. The market is characterized by a moderate level of merger and acquisition (M&A) activity by the leading players. This is due to several factors, including the desire to expand the business to cater to the growing demand for medical service robots. A report from Grand View Research said that the global medical service robots market size was estimated at USD 20.59 billion in 2024 and is projected to grow at a CAGR of 16.5% from 2025 to 2030. It said: "The growth can be attributed to the introduction of technologically advanced robotic equipment in the healthcare sector and the rise in per capita healthcare spending. Continuous advancements in technology, such as robotic catheter control systems (CCS), data recorders, data analytics, remote navigation, motion sensors, 3D-Imaging, and HD surgical microscopic cameras, are projected to drive industry growth. Furthermore, the introduction of swarm robotics is opening new opportunities for industry. It is a new approach to coordinating multi-robotic systems through swarm intelligence." Active Tech Companies in the markets today include Jeffs' Brands Ltd (NASDAQ: JFBR), Serve Robotics Inc. (NASDAQ: SERV), Symbotic Inc. (NASDAQ: SYM), Microbot Medical Inc. (NASDAQ: MBOT), Medtronic plc (NYSE: MDT).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×